Clinical Trials Logo

Lupus Nephritis clinical trials

View clinical trials related to Lupus Nephritis.

Filter by:

NCT ID: NCT01042457 Completed - Lupus Nephritis Clinical Trials

Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis

Start date: May 2009
Phase: Phase 3
Study type: Interventional

To evaluate therapeutic response to MMF treatment in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis. Mycophenolic acid levels at 1-hour post dose will be monitored monthly up to 6 months.

NCT ID: NCT01015456 Terminated - Lupus Nephritis Clinical Trials

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

CONTROL
Start date: January 2010
Phase: Phase 3
Study type: Interventional

To investigate the efficacy and safety of enteric-coated mycophenolate sodium (Myfortic) as compared to intravenous cyclophosphamide in the treatment of active nephritis. The primary outcomes are complete and partial renal remission, as assessed by renal function, urinary sediment and proteinuria in patients with International Society of Nephrology/ Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis.

NCT ID: NCT00976300 Completed - Clinical trials for Systemic Lupus Erythematosus

Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study

CYCLOFA-LUNE
Start date: January 2002
Phase: Phase 2
Study type: Interventional

Intravenous cyclophosphamide is considered to be the standard of care for treatment of proliferative lupus nephritis. However, its use is limited by potentially severe toxic effects. Cyclosporine A has been suggested to be an efficient and safe treatment alternative to cyclophosphamide. In a randomized, multicenter, open-label, controlled trial the investigators sought to compare the efficacy of oral cyclosporine A with intravenous pulse cyclophosphamide to induce durable remission in patients with lupus nephritis III-IV.

NCT ID: NCT00935389 Completed - Lupus Nephritis Clinical Trials

Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria

Start date: April 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) and CTX in LN-V patients with gross proteinuria.

NCT ID: NCT00908986 Withdrawn - Lupus Nephritis Clinical Trials

Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis

Start date: December 2008
Phase: N/A
Study type: Interventional

The objective of this study is to assess the as efficacy of rituximab as induction therapy in membranous lupus nephritis. Safety and tolerability will additionally be assessed. Subjects will receive open-label 2 courses of rituximab at baseline and at 6 months. They will be followed monthly for 18 months to assess response and durability of response. The hypothesis: B cell depletion will be an effective safe and well tolerated treatment for membranous lupus nephritis (Class V).

NCT ID: NCT00881309 Completed - Lupus Nephritis Clinical Trials

To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis

Start date: March 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to: - To access the efficacy of TW compared to Aza in the maintenance therapy for lupus nephritis - To investigate the safety and tolerability of TW versus Aza in the maintenance therapy for lupus nephritis

NCT ID: NCT00876616 Completed - Lupus Nephritis Clinical Trials

Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis

Start date: April 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of multi-target therapy in the treatment of class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ lupus nephritis.

NCT ID: NCT00774852 Completed - Lupus Nephritis Clinical Trials

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

ACCESS
Start date: November 2008
Phase: Phase 2
Study type: Interventional

This study is for individuals with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself.

NCT ID: NCT00709722 Completed - Lupus Nephritis Clinical Trials

Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis

Start date: October 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the open multi-center study is to determine an efficient and safe dose and dosing schedule of NKT-01 in induction of response in treatment of lupus nephritis.

NCT ID: NCT00705367 Completed - Lupus Nephritis Clinical Trials

Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg

Start date: August 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus (SLE)